DE69131292T2 - Antikoagulierende proteine - Google Patents

Antikoagulierende proteine

Info

Publication number
DE69131292T2
DE69131292T2 DE69131292T DE69131292T DE69131292T2 DE 69131292 T2 DE69131292 T2 DE 69131292T2 DE 69131292 T DE69131292 T DE 69131292T DE 69131292 T DE69131292 T DE 69131292T DE 69131292 T2 DE69131292 T2 DE 69131292T2
Authority
DE
Germany
Prior art keywords
factor vii
modified
wild
coagulation cascade
anticoagulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131292T
Other languages
English (en)
Other versions
DE69131292D1 (de
Inventor
Kathleen Berkner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DE69131292D1 publication Critical patent/DE69131292D1/de
Publication of DE69131292T2 publication Critical patent/DE69131292T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69131292T 1990-01-29 1991-01-25 Antikoagulierende proteine Expired - Fee Related DE69131292T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47131390A 1990-01-29 1990-01-29
PCT/US1991/000552 WO1991011514A1 (en) 1990-01-29 1991-01-25 Anticoagulant proteins

Publications (2)

Publication Number Publication Date
DE69131292D1 DE69131292D1 (de) 1999-07-08
DE69131292T2 true DE69131292T2 (de) 1999-09-30

Family

ID=23871126

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131292T Expired - Fee Related DE69131292T2 (de) 1990-01-29 1991-01-25 Antikoagulierende proteine

Country Status (8)

Country Link
US (2) US5288629A (de)
EP (1) EP0521873B1 (de)
JP (2) JP3330932B2 (de)
AT (1) ATE180834T1 (de)
AU (1) AU651573B2 (de)
CA (1) CA2074839C (de)
DE (1) DE69131292T2 (de)
WO (1) WO1991011514A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
WO1991018001A1 (en) * 1990-05-17 1991-11-28 Dana-Farber Cancer Institute Trans-dominant suppressor genes for oligomeric proteins
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
HU218890B (hu) * 1991-02-28 2000-12-28 Novo Nordisk A/S Véralvadást gátló módosított VII faktorok, ezeket kódoló polinukleotid molekulák, polinukleotid molekulával transzfektált emlős sejtek és a véralvadást gátló módosított VII faktorokat tartalmazó gyógyászati készítmények, valamint a készítmények ...
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
PT699075E (pt) * 1993-05-21 2002-05-31 Novo Nordisk As Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas
WO1994028017A1 (en) * 1993-06-01 1994-12-08 The Scripps Research Institute Human mutant tissue factor compositions useful as tissue factor antagonists
DE69413817T2 (de) * 1993-06-18 1999-06-10 Nycomed Imaging As Faktor vii-peptide
US5510248A (en) * 1993-06-22 1996-04-23 The University Of British Columbia Stable recombinant meizothrombin-like polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AR017831A1 (es) * 1997-12-10 2001-10-24 Pioneer Hi Bred Int Metodo para alterar la composicion de aminoacidos de una proteina nativa de interes, proteina elaborada, y polinucleotido
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
AU781618C (en) 1999-07-02 2006-03-16 Genentech Inc. FVIIa antagonists
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
PL206148B1 (pl) 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
AU2001249389A1 (en) * 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) * 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
CN101486761A (zh) * 2000-09-13 2009-07-22 诺沃挪第克健康护理股份公司 人凝血因子vii变体
EP2253703A1 (de) 2000-09-13 2010-11-24 Novo Nordisk Health Care AG Varianten des menschlichen Gerinnungsfaktors VII
AU2002245204A1 (en) * 2000-10-25 2002-07-24 Genzyme Corporation Methods for treating blood coagulation disorders
WO2002038162A1 (en) * 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
HUP0401124A3 (en) 2001-03-22 2006-01-30 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
JP4537059B2 (ja) 2001-09-27 2010-09-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US6960657B2 (en) * 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
CN1665925A (zh) 2002-04-30 2005-09-07 马克西根控股公司 凝血因子Ⅶ或Ⅶa多肽变体
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US6911323B2 (en) * 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
CA2840692A1 (en) * 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
BRPI0408417A (pt) 2003-03-18 2006-03-21 Novo Nordisk Healthcare Ag métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição
MXPA05009914A (es) * 2003-03-18 2006-01-09 Novo Nordisk Healthcare Ag Composiciones farmaceuticas acuosas, liquidas de polipeptidos del factor vii.
US7771996B2 (en) 2003-03-20 2010-08-10 Bayer Healthcare Llc FVII or FVIIa variants
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
MXPA05012476A (es) * 2003-05-23 2006-02-22 Novo Nordisk Healthcare Ag Estabilizacion de proteina en solucion.
BRPI0411650A (pt) * 2003-06-19 2006-08-08 Maxygen Holdings Ltd variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
CN1863908B (zh) 2003-09-09 2010-08-04 诺和诺德医疗保健公司 凝固因子ⅶ多肽
CA2546580A1 (en) * 2003-11-18 2005-06-09 Iconic Therapeutics, Inc. Homogeneous preparations of chimeric proteins
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR20060109950A (ko) * 2003-12-19 2006-10-23 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
WO2005075635A2 (en) * 2004-02-03 2005-08-18 Novo Nordisk Health Care Ag Coagulation factor vii/viia variants lacking a functional lipid membrane binding domain
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
WO2007039475A1 (en) * 2005-09-21 2007-04-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
EP2004214B1 (de) * 2006-03-16 2012-11-07 STELLARIS PHARMACEUTICALS Aps Lokale behandlung mit faktor vii
JP5122562B2 (ja) * 2006-07-17 2013-01-16 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
EP2147096B1 (de) * 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modifizierte Faktor-VII-Polypeptide und Verwendungen davon
EP2170919B8 (de) 2007-06-12 2016-01-20 ratiopharm GmbH Verbessertes verfahren zur herstellung von nukleotidzuckern
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
HUE037163T2 (hu) 2009-06-09 2018-08-28 Prolong Pharmaceuticals Llc Hemoglobin készítmények
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP3833381B1 (de) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
ATE74164T1 (de) * 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) * 1987-06-25 1987-06-25 Novo Industri As Protein
EP0296413A2 (de) * 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrides Protein C und Verfahren zur Herstellung
US4994371A (en) * 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors

Also Published As

Publication number Publication date
CA2074839A1 (en) 1991-07-30
AU651573B2 (en) 1994-07-28
JP3330932B2 (ja) 2002-10-07
EP0521873B1 (de) 1999-06-02
EP0521873A4 (en) 1993-05-05
US5288629A (en) 1994-02-22
JPH05500161A (ja) 1993-01-21
WO1991011514A1 (en) 1991-08-08
ATE180834T1 (de) 1999-06-15
EP0521873A1 (de) 1993-01-13
AU7300291A (en) 1991-08-21
JP2002247996A (ja) 2002-09-03
CA2074839C (en) 2000-11-14
US5824639A (en) 1998-10-20
DE69131292D1 (de) 1999-07-08

Similar Documents

Publication Publication Date Title
DE69131292T2 (de) Antikoagulierende proteine
Elg et al. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor
CA1244763A (en) Blood coagulation inhibiting proteins, processes for preparing them and their uses
Elg et al. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits
Bajwa et al. Thrombin-like and fibrinolytic enzymes in the venoms from the Gaboon viper (Bitis gabonica), eastern cottonmouth moccasin (Agkistrodon p. piscivorus) and southern copperhead (Agkistrodon c. contortrix) snakes
AU3050384A (en) Removal of lipid containing virus in blood
CA2060507A1 (en) Factor xa based anticoagulant compositions
Gitel et al. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications
US5922358A (en) Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications
US5637299A (en) Enhancement of thrombolytic therapy with deglycosylated forms of plasminogen
Nagaki et al. Inactivator of the First Component of Human Complement (CĪINA) Enhancement of CĪlNA Activity against CĪs by Acidic Mucopolysaccharides
Bara et al. Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin
Grotto et al. Effect of purified Vipera palestinae hemorrhagin on blood coagulation and platelet function
Weinstein et al. Enhancement of rabbit protein S anticoagulant cofactor activity in vivo by modulation of the protein S C4B binding protein interaction.
Ku et al. Modulation of fibrin clot formation by human serum amyloid P component (SAP) and heparin.
Seegers et al. Autocatalysis in prothrombin activation
Pejler Procoagulant and anticoagulant activities of resident and inflammatory peritoneal cells
CN109316599A (zh) 一种抑肽酶或其突变体、衍生物、类似物或其组成片段的应用
JPH07291999A (ja) 血小板安定化因子ｉｘ−フラグメント、その製造方法及びこれを含有する薬剤
Thelin et al. The action of thrombin on serum albumin
EP1181046B1 (de) 10-formyltetrahydrofolate dehydrogenase als therapeutischen mittel
EP0326013A3 (de) Von menschlichem alpha-2-Plasmin-Inhibitor abgeleitete neue Proteine oder Proteine, die diesen ähnlich sind
Chamone Physiological aspects and clinical application of heparin
SUMI et al. Enzymatic production of acid stable trypsin-plasmin inhibitor (ASTI) in human plasma
Gurewich et al. A mechanism for the potentiating effect of urokinase (UK) or tissue plasminogen activator (t-PA) on clot lysis by pro-urokinase (pro-uk)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: VONNEMANN, KLOIBER & KOLLEGEN, 80796 MUENCHEN

8339 Ceased/non-payment of the annual fee